Skip to main content

Table 2  Demographics details, clinical data, and laboratory data according to the occurrence of acute kidney injury during ICU stay

From: Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy

  Acute kidney injury p
No ( N = 30) Yes ( N = 123)
Age (years) 48.50 (31.50–64.75) 63.00 (50.50–70.00) 0.004
Male 12 (40.0) 93 (75.6)  < 0.001
G6PD deficiency 1 (3.3) 8 (6.5) 0.819
Underlying malignancy    0.452
 Solid cancer 0 (0) 2 (2.3)  
 Leukemia 13 (43.3) 39 (31.7)  
 Non-Hodgkin lymphoma 17 (56.7) 73 (59.3)  
 Multiple myeloma 0 (0.0) 2 (1.6)  
 Other 0 (0.0) 7 (5.7)  
 Spontaneous TLS 12 (40.0) 78 (63.4) 0.033
 Nephrotoxic use 6 (20.0) 48 (39.0) 0.082
Cardiovascular risk    
 Chronic hypertension 5 (16.7) 41 (33.3) 0.118
 Diabetes 2 (6.7) 17 (13.8) 0.449
 Cardiovascular event 2 (6.7) 13 (10.6) 0.763
 Chronic kidney disease 2 (6.7) 8 (6.6) 1.000
 HIV positive status 1 (3.3) 25 (20.3) 0.051
 mSOFA score 4.00 (2.00–4.75) 5.00 (2.00–7.00) 0.021
 Vasopressors 1 (3.3) 23 (18.7) 0.073
 Mechanical ventilation 2 (6.7) 32 (26.0) 0.041
 Rasburicase use 24 (80.0) 90 (73.2) 0.592
Laboratory data at admission    
 Kalemia, mEq/L 4.10 (3.70–4.70) 4.60 (4.00–5.00) 0.084
 Phosphatemia, mg/dL 3.53 (2.82–4.37) 4.71 (3.49–6.18) 0.003
 Calcemia, mg/dL 8.94 (8.17–9.48) 8.68 (7.80–9.44) 0.421
 Uricemia, mg/dL 6.84 (5.38–9.32) 8.78 (5.17–13.10) 0.166
 LDH, UI/L 2700 (2008–4630) 2855 (1466–5286) 0.925
ICU mortality 3 (10.0) 24 (19.5) 0.338
One-year mortality 11 (36.7) 75 (61.0) 0.028
One-year remission 16 (53.3) 38 (30.9) 0.036
  1. Results are reported as n (%) or median (IQR)
  2. G6PD glucose 6 phosphate dehydrogenase, TLS tumor lysis syndrome, HIV human immunodeficiency virus, mSOFA modified Sequential Organ Failure Assessment, LDH lactate dehydrogenase, ICU intensive care unit